Give him 90 seconds, and Dr. Stephen Ellis will explain how iFR has improved the prospects for physiologic assessment over what FFR has offered — and why it matters.
Despite the equivocal results of the ABSORB trials to date, the key question remains what happens over the long term with these devices.
Colleagues of the late interventional cardiologist Patrick Whitlow, MD, give a sense of why he was honored with the prestigious Master Clinical Operator Award at this year’s Transcatheter Cardiovascular Therapeutics conference.
A new meta-analysis shows IVUS’ edge over angiography for guiding stent placement extends to drug-eluting stents as well as bare-metal stents. But that doesn’t mean IVUS makes sense for lower-risk patients.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
After Cleveland Clinic introduced four key process improvements to standardize acute management of STEMI patients, door-to-balloon times went from good to exceptional. Here’s the backstory.
An FDA advisory panel just recommended approval of what may be the nation’s first bioresorbable stent. Here’s why an ABSORB III trial investigator wasn’t surprised that interim results didn’t find it superior to a standard DES.
The year just passed was full of insights and innovations likely to be felt for many years to come. Here are 15 such developments in which Cleveland Clinic staff played key roles.
Percutaneous coronary intervention can now be considered in selected hemodynamically stable patients with multivessel disease. An expert from the guideline writing committee provides the backstory.
Adjunctive intracoronary radiation therapy is a treatment modality that still has value even in the era of drug-eluting stents. Vascular brachytherapy is now an option again at Cleveland Clinic in carefully selected patients.
The ABSORB trial is assessing a new bioabsorbable device designed to match the performance of metallic drug-eluting stents before it dissolves to avoid long-term thrombotic risk.